|Bid||0.00 x 2200|
|Ask||172.65 x 800|
|Day's Range||73.13 - 74.87|
|52 Week Range||52.83 - 75.99|
|Beta (3Y Monthly)||0.60|
|PE Ratio (TTM)||154.31|
|Earnings Date||Jan 31, 2019 - Feb 4, 2019|
|Forward Dividend & Yield||2.20 (2.94%)|
|1y Target Est||79.12|
Risk markets continue to deliver mixed messages to traders and market participants. The latest price action suggests more downside -- but first -- with a possible bounce to the 2750 level in the S&P 500, says Yahoo Finance's Jared Blikre, who breaks it down with Jen Rogers and Myles Udland.
The FDA's Anesthetic and Analgesic Drug Products Advisory Committee and Drug Safety and Risk Management Advisory Committee vote for Mallinckrodt (MNK) abuse-deterrent drug.
Merck's (MRK) Keytruda meets primary endpoint of overall survival in a phase III study evaluating it for the second-line treatment of advanced esophageal cancer.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peak (Biotech stocks hitting 52-week highs on Nov. 13) AstraZeneca plc (NYSE: AZN ) Down In The Dumps (Biotech ...
Merck & Co's blockbuster drug Keytruda met the main goal of a late-stage trial testing the treatment in patients with cancers of the digestive tract, the U.S. drugmaker said on Wednesday. Keytruda, among a class of medicines called PD-1 inhibitors, is Merck's top selling drug and has already been approved to treat several forms of cancer including skin and lung cancer. Keytruda, when compared to chemotherapy, enabled certain patients with esophageal cancer to live longer, helping the drug meet the main goal of the late-stage study, Merck said.
With Pivotal KEYNOTE-181 Trial Meeting Primary Endpoint of OS, KEYTRUDA Becomes the First Anti-PD-1 Therapy to Demonstrate a Survival Benefit for These Patients
Most investors tend to think that hedge funds and other asset managers are worthless, as they cannot beat even simple index fund portfolios. In fact, most people expect hedge funds to compete with and outperform the bull market that we have witnessed over the past few years. However, hedge funds are generally partially hedged and […]
Merck (MRK), known as MSD outside the United States and Canada, today announced that it has started the submission of a rolling Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for V920 (rVSV∆G-ZEBOV-GP, live attenuated), the company’s investigational vaccine for Ebola Zaire disease. This rolling submission is made pursuant to the FDA’s Breakthrough Therapy Designation for V920, which was announced by the company in July 2016.